Home Cellular science Amaroq Therapeutics Takes First Steps and Makes Key Scientific Advisory Board Appointments

Amaroq Therapeutics Takes First Steps and Makes Key Scientific Advisory Board Appointments


Promising ‘dark matter’ cancer therapy has clinical trials in sight

DUNEDIN, New Zealand, June 8, 2022 /PRNewswire/ — Amaroq Therapeutics, a biotech company focused on developing a new class of therapeutics targeting lncRNA in cancer, is advancing towards clinical trials after a promising initial development phase and earning key nominations at within its Scientific Advisory Board (SAB).

Amaroq Therapeutics is pleased to announce the first milestone achievements and appointment of Teacher David L. Spector (chair), Teacher Sherene Law, Teacher Anna Pyleand Doctor Henrik Orum as members of the SAB.

“We are truly fortunate to welcome four leading experts to our Board of Directors. With a mix of expertise in cancer research, RNA biology, drug development and clinical trials, Amaroq has never been better supported to advance our therapy to market,” says Dr. Sarah DiermeierScientific Director and Founder, Amaroq Therapeutics.

These nominations from industry leaders from the scientific community are a great mark of confidence in our development of RNA therapy. This brings us much closer to clinical trials and delivering potentially breakthrough treatments to patients with some of the most common cancers,” says Diermeier.

Amaroq Therapeutics is one of the first companies in the world to explore long non-coding RNAs (ncRNAs), often referred to as the “dark matter” of the genome, for applications in oncology. Their newly strengthened team of experts is exploring the use of lncRNA molecules as therapeutic targets and diagnostic markers in the treatment of cancer.

Amaroq Therapeutics research has shown that specific lncRNA molecules are highly expressed in cancer cells, but not in normal healthy cells. Removing these lncRNA molecules from cancer cells can slow down the process of cell division.

“This gives us very real hope that lncRNA molecules may hold the key to treating many common forms of cancer such as breast, colorectal and liver cancer,” says Diermeier. “The next generation of RNA-based therapies we are developing could be the breakthrough treatment the world has been waiting for to treat cancers – one of the world’s deadliest and most debilitating diseases.”

Led by Brandon Capital and backed by Otago Innovation Ltd, NZ Innovation Booster and Cure Kids Ventures, a total of $14 million has been invested in Amaroq Therapeutics to date.

“We are delighted to continue to support Amaroq Therapeutics towards clinical development, and the very high level of experience and expertise among the new board members speaks to the potential we all see in them as pioneers of RNA therapy. We will be watching with keen interest,” says Duncan MackintoshChief Investment Officer at Brandon Capital Partners.

New appointments to the board of directors of Amaroq SAB:

Teacher David L. SpectorChair

David L. Spector, Ph.D., is a professor and research director at Cold Spring Harbor Laboratory. He is co-lead of the Gene Regulation and Inheritance program at the National Cancer Institute designated Cold Spring Harbor Laboratory Cancer Center. In 2014, he was elected to the American Academy of Arts and Sciences and as a foreign associate member of the European Molecular Biology Organization. In 2017, he was elected a Life Member of the American Society of Cell Biology for his distinguished contributions to the advancement of cell biology.

Teacher Sherene Law

Sherene Law is a medical oncologist specializing in the treatment of breast cancer and group leader at the Peter MacCallum Cancer Centre, Melbourne, Australia. She is internationally recognized as a leading clinician scientist whose work has led to new insights into the field of breast cancer immunology, including an immune biomarker and the formation of the international TILs working group. Professor Loi’s research is highly cited – she has been ranked in the top 1% of most cited researchers in the world by the Web of Science since 2018. She co-chairs the International Breast Cancer Study Group (IBCSG) based in Bern, Switzerland, which conducts breast cancer clinical trials in more than 16 countries. She is currently the inaugural chair of the National Breast Cancer Foundation (NBCF) of Australia and a researcher at the Breast Cancer Research Foundation (BCRF), New York.

Teacher Anna Marie Pyle

Anna Marie Pyle is a Yale Sterling Professor of Molecular, Cellular, and Developmental Biology and Chemistry, and a research fellow at the Howard Hughes Medical Institute. Dr. Pyle formed her own research group in 1992 in the Department of Biochemistry and Molecular Biophysics at Colombia University Medical Center. In 2002, she moved to Yale University, where his group specializes in determining the structure and function of large RNA molecules and associated protein enzymes. Pyle is Past President of the RNA Society, she is Vice Chair of the Brookhaven National Laboratory Science and Technology Steering Committee, and serves on the Scientific Advisory Board of Arrakis Therapeutics and RADD Pharma.

Dr. Henrik Orum

Henrik Ørum brings over 25 years of experience in all aspects of starting, building, leading and exiting successful biotechnology companies. dr. Ørum began his career in biotechnology at PNA Diagnostics A/S in 1993, serving as Scientific Director from 1993 to 1999. During his tenure, the company was sold to Boehringer Mannheim in 1994 and then to Hoffman-La Roche in 1997 In 1996, Dr. Ørum co-founded Exiqon A/S, a nucleic acid diagnostics company listed on the Copenhagen Stock Exchange in 2007. In 2000, he co-founded Santaris Pharma A/S, where he served as Chief Scientific Officer and Vice President Business Development ‘upon the acquisition of the company by Roche in 2014. In 2017, Dr. Ørum founded CiVi Biopharma Inc, where he serves as Chief Scientific Officer.

About Amaroq Therapeutics

Amaroq Therapeutics is a New Zealandbiotechnology company based on the development of a new class of therapeutic products targeting lncRNAs in cancer.

Long non-coding RNAs are a relatively recently discovered class of molecules, often referred to as the “dark matter” of the human genome. These natural molecules do not code for proteins but perform important regulatory functions in the cell that could be exploited as a new therapeutic approach for multiple indications. Amaroq’s research team discovered ncRNA molecules that are highly expressed in cancer cells and once removed, cancer cell growth slows. Amaroq Therapeutics develops innovative therapies to target lncRNAs for the treatment of cancer.

Amaroq Therapeutics is funded by the Medical Research Commercialization Fundmanaged by a life sciences venture capital firm Brandon Capital Partners, Otago Innovation Ltd, University of Otago, Heal the childrenand New Zealand Innovation Booster. The company grew out of research from the University of Otago in Dunedin, New Zealand.

About Brandon BioCatalyst and Brandon Capital

Brandon Capital is Australasia’s leading life sciences venture capital firm, with a strong global presence supported by key partnerships and team members in the US and UK. From seed investment to expansion capital, Brandon Capital supports life sciences companies from proof of concept to commercialization.

Managed by Brandon Capital, Brandon BioCatalyst is a unique collaboration of more than 50 leading medical research institutes, investors and governments united by a single goal: to advance the next generation of medical therapies and technologies that improve health and save lives. lives.

www.brandoncapital.vc | www.brandonbiocatalyst.com

SOURCE Amaroq Therapeutic